Two-Drug Cocktail Active against RCC.
The combination of avelumab and axitinib increases progression-free survival by 64% over sunitinib in patients with advanced renal cell carcinoma. The drug duo triggered responses in 51% of patients, whereas sunitinib induced responses in 26%. Side effects of grade 3 or 4 were similar in both groups of patients.